zt002
Cell therapyexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 5, 2022 (NCT05491421)
Timeline
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07230119 | Phase 3 | Mar 8, 2026 | Beijing QL Biopharmaceutical Co.,Ltd, Peking University |
| NCT07020884 | Phase 2 | Aug 14, 2024 | Beijing QL Biopharmaceutical Co.,Ltd, Peking University |
| NCT07065032 | Phase 1/Phase 2 (Phase 2) | Feb 19, 2024 | Beijing QL Biopharmaceutical Co.,Ltd, Qingdao University |
| NCT06371326 | Phase 1 | Nov 21, 2023 | Beijing QL Biopharmaceutical Co.,Ltd, Bengbu Medical College |
| NCT06423872 | Phase 1 | Jun 19, 2023 | Beijing QL Biopharmaceutical Co.,Ltd, Peking University |
| NCT05491421 | Phase 1 | Sep 5, 2022 | Beijing QL Biopharmaceutical Co.,Ltd, Novotech, Nucleus Network Ltd, QL Biopharmaceutical Australia Pty Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing QL Biopharmaceutical Co.,Ltd | For profit | 6 | 5 | 3 | 2022 |
| Peking University | Academic/Hospital | 3 | 0 | 3 | 2023 |
| Bengbu Medical College | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2022 |
| Qingdao University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| QL Biopharmaceutical Australia Pty Ltd | For profit | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1